Biotech News

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

Humacyte (HUMA)HumacyteConference / presentation

- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim

Related news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

Stock data

Close
0.64 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States